Oncology Research Editorial Office

Oncology Research, Vol.33, No.7, pp. 1801-1802, 2025, DOI:10.32604/or.2025.068988 - 26 June 2025

Abstract This article has no abstract. More >

FANG CHEN¹, DONGQIANG YANG², YUHUA RU³, SHAN CAO¹, AISHE GAO¹

Oncology Research, Vol.33, No.7, pp. 1799-1800, 2025, DOI:10.32604/or.2025.064363 - 26 June 2025

Abstract This article has no abstract. More >

Yanxi Peng¹, Honggen Yuan¹, Zhanjie Jiang², Xiaoqing Ou², Qian Zhang³, Kexin Yi¹, Yanbin Meng², Qun Xie^1,*

Oncology Research, Vol.33, No.7, pp. 1679-1693, 2025, DOI:10.32604/or.2025.062747 - 26 June 2025

Abstract Background: Expression of mRNA is widely regulated by N6-methyladenosine (m⁶A). An increasing number of studies have shown that m⁶A methylation, facilitated by methyltransferase 3 (METTL3), is crucial in the progression of tumors. Previous reports have indicated the involvement of both METTL3 and c-Src kinase in the evolution of liver cancer. However, the potential connection between c-Src and the METTL3-mediated mechanism in liver cancer progression remains elusive. Methods: The correlation expression between c-Src and METTL3 between liver cancer patients and the control group was analyzed using the TCGA database, and was further demonstrated by Western blot and… More >

CHENG CHENG^1,2,3, CHAO SHI^1,2, SHANG WU^1,2, WEIXING WU³, JINGPING LI^1,2, SINUO GAO^1,2, MENG HAN³, YIMIN WANG³, XIANGMEI ZHANG^2,4,*, YUNJIANG LIU^1,2,*

Oncology Research, Vol.33, No.7, pp. 1633-1648, 2025, DOI:10.32604/or.2025.061637 - 26 June 2025

Abstract Objectives: While programmed cell death 1 (PD-1) inhibitors have improved cancer treatment, the function and mechanisms of programmed cell death ligand 1 (PD-L1), particularly when expressed by cancer cells, remain unclear. This study aims to explore the role of PD-L1 within breast cancer cells and identify key targets for future immunotherapy. Methods: RNA-seq was performed on breast cancer cells with silenced PD-L1 to screen for differentially expressed genes, followed by bioinformatics analysis. Clinical specimens from breast cancer patients undergoing primary surgery without preoperative treatment were collected, along with in vitro analysis to validate the potential mechanism. Results:… More >

LICHEN XU^1,2, PAN ZHANG³, GUIQI ZHANG², ZHAOLIANG SHEN⁴, XIZHUANG BAI^1,3,*

Oncology Research, Vol.33, No.7, pp. 1797-1798, 2025, DOI:10.32604/or.2024.061279 - 26 June 2025

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.33, No.6, pp. 1507-1507, 2025, DOI:10.32604/or.2024.056917 - 29 May 2025

Abstract This article has no abstract. More >

THAINá RODRIGUES^1,2, PATRíCIA CANDIDO^1,3, FERES CAMARGO MALUF¹, POLIANA ROMãO¹, CAROLINA MIE MIOSHI¹, VANESSA RIBEIRO GUIMARãES¹, JULIANA ALVES DE CAMARGO¹, KARINA SERAFIM DA SILVA^1,4, GABRIEL ARANTES DOS SANTOS¹, IRAN AMORIM SILVA¹, KATIA RAMOS MOREIRA LEITE¹, WILLIAM C. NAHAS⁵, SABRINA T. REIS^1,3, RUAN PIMENTA^1,6, NAYARA IZABEL VIANA^1,7,*

Oncology Research, Vol.33, No.6, pp. 1377-1382, 2025, DOI:10.32604/or.2025.055306 - 29 May 2025

Abstract Objectives: Bladder Cancer (BC) is one of the most commonly diagnosed malignancies worldwide, with high rates of mortality and morbidity. It can be classified as non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC), with radical cystectomy being the treatment for MIBC, which significantly reduces quality of life. MicroRNAs (miRs) act as critical genetic regulators, with both oncogenic and tumor-suppressive roles. MiR-10a is described as a tumor suppressor in various neoplasms, but its role in BC is controversial. This study aims to assess the activity of miR-10a in cellular invasion and proliferation in two… More >

Jin Liu^1,2, Xiu Zhang¹, Xiao Hu², Gaofeng Yuan², Kai Chen^1,*

BIOCELL, Vol.49, No.4, pp. 665-680, 2025, DOI:10.32604/biocell.2025.063296 - 30 April 2025

Abstract Objective: This study examines the significance and functions of CLDN9 in gastric cancer (GC), intending to identify novel targets for diagnosis and treatment. Methods: CLDN9 expression in GC tissues and cell lines was investigated in TCGA data, with analysis with Western blotting, qRT-PCR, and immunohistochemical analyses. Correlations between clinicopathological characteristics, progression-free survival (PFS), and overall survival (OS) were assessed with Cox regression. The effect of CLDN9 knockdown/overexpression on tumorigenic functions (proliferation, migration, and invasion) was assessed using CCK-8, colony formation, and Transwell assays. Tumor-bearing assays were performed to verify the impact of CLDN9 knockdown on… More >

Oncology Research Editorial Office

Oncology Research, Vol.33, No.5, pp. 1251-1252, 2025, DOI:10.32604/or.2025.065346 - 18 April 2025

Abstract This article has no abstract. More >

YU QIU^1,#, RUIHAN LIU^2,#, SHANSHAN HUANG¹, QIAOTING CAI¹, YI XIE¹, ZHITING HE¹, WEIGE TAN^2,*, XINHUA XIE^1,*

Oncology Research, Vol.33, No.5, pp. 1135-1147, 2025, DOI:10.32604/or.2025.062767 - 18 April 2025

Abstract Objectives: Deubiquitinase OTUB2 plays a critical role in the progression of various tumors. However, its specific role in triple-negative breast cancer (TNBC) remains unclear. This study aims to elucidate the biological function of OTUB2 in TNBC and uncover the underlying mechanisms. Methods: First, we found that the expression of OTUB2 was upregulated in TNBC by bioinformatics analysis, we then validated its expression in TNBC tissues and cells using immunohistochemistry (IHC) and qPCR and plotted the survival curves by Kaplan-Meier method. Gene set enrichment analysis (GSEA) suggested that OTUB2 may be involved in tumor proliferation and metastasis.… More > Graphic Abstract